title: Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement.
abstract: Bone metastases represents a common cause of morbidity in patients suffering many types of cancer: breast, lung, kidney, prostate, and multiple myeloma. Osteolytic metastases often cause severe pain, pathologic fractures, hypercalcemia, spinal cord compression, and other nerve-compression syndromes. Osteoclasts (OCs), cells deriving from granulocitic-macrophagic lineage, are responsible for osteolysis, which may be reduced by inhibiting both OCs formation and activity. By studying bone osteolytic metastases mechanism in solid tumors, we report here our findings that cancer patients with bone involvement display an increase in osteoclasts precursors, compared with both healthy controls and cancer patients without bone metastases. Peripheral blood mononuclear cells (PBMCs) from patients with osteolytic lesions show osteoclastogenesis without adding M-CSF, RANKL, or TNF-alpha. However, these factors are necessary to generate OCs from healthy donors, non-osteolytic patient PBMCs and T-cell depleted PBMCs. OCs derived from cancer patients show more resorption pits than OCs from healthy donors and express genes involved in osteoclastogenesis. Our data show that a spontaneous osteoclastogenesis occurs in patients affected by osteolytic lesions and may be supported by factors released by T lymphocytes. These factors could give a priming to osteoclast precursors and promote osteoclastogenesis. In fact, T-cell depleted PBMCs do not differentiate into OCs without adding M-CSF and RANKL. Moreover, we do not obtain a higher number of OCs by increasing RANKL doses in cultures, and OCs and T lymphocytes mRNA level are detected for TNF-alpha but not for RANKL. The addition of OPG to PBMCs cultures do not modify spontaneous osteoclastogenesis. A neutralizing anti-TNF-alpha antibody in unstimulated PBMC cultures of osteolytic cancer patients induces an inhibition of osteoclastogenesis. These data suggest that TNF-alpha may be responsible for osteoclastogenesis in these tumors.
authors.affiliation: Center for Experimental Research and Medical Studies, University and A.S.O. San Giovanni Battista, Turin, Italy. roato78@libero.it <roato78@libero.it>
authors.forename: Ilaria
authors.initials: I
authors.lastname: Roato
authors.forename: Maria
authors.initials: M
authors.lastname: Grano
authors.forename: Giacomina
authors.initials: G
authors.lastname: Brunetti
authors.forename: Silvia
authors.initials: S
authors.lastname: Colucci
authors.forename: Antonio
authors.initials: A
authors.lastname: Mussa
authors.forename: Oscar
authors.initials: O
authors.lastname: Bertetto
authors.forename: Riccardo
authors.initials: R
authors.lastname: Ferracini
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000473:pathology*; D001862:Bone Resorption / Q000378:metabolism; D002478:Cells, Cultured; D005260:Female; D015870:Gene Expression; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D005819:Genetic Markers / Q000235:genetics; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000473:pathology; D010010:Osteoclasts / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology; D010641:Phenotype; D013601:T-Lymphocytes / Q000737:chemistry / Q000378:metabolism
chemical_list: D005819:Genetic Markers